Mar Vista Investment Partners LLC Has $56.50 Million Position in Johnson & Johnson (NYSE:JNJ)

Mar Vista Investment Partners LLC lessened its position in Johnson & Johnson (NYSE:JNJFree Report) by 7.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 362,741 shares of the company’s stock after selling 27,974 shares during the period. Johnson & Johnson comprises about 2.7% of Mar Vista Investment Partners LLC’s portfolio, making the stock its 19th largest holding. Mar Vista Investment Partners LLC’s holdings in Johnson & Johnson were worth $56,497,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. DORCHESTER WEALTH MANAGEMENT Co lifted its stake in shares of Johnson & Johnson by 8.6% during the 1st quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock worth $14,975,000 after buying an additional 5,327 shares during the last quarter. Cantor Fitzgerald Investment Advisor L.P lifted its stake in shares of Johnson & Johnson by 88.9% during the 1st quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock worth $31,049,000 after buying an additional 82,429 shares during the last quarter. AMI Investment Management Inc. lifted its stake in shares of Johnson & Johnson by 8.8% during the 1st quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock worth $3,244,000 after buying an additional 1,475 shares during the last quarter. Equitable Holdings Inc. lifted its stake in shares of Johnson & Johnson by 4.9% during the 1st quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock worth $8,095,000 after buying an additional 2,119 shares during the last quarter. Finally, USS Investment Management Ltd lifted its stake in shares of Johnson & Johnson by 2.4% during the 1st quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock worth $152,488,000 after buying an additional 20,528 shares during the last quarter. Institutional investors own 68.40% of the company’s stock.

Johnson & Johnson Trading Up 0.8 %

NYSE:JNJ opened at $157.86 on Wednesday. The firm’s fifty day moving average is $158.30 and its 200-day moving average is $158.06. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.96 and a current ratio of 1.16. Johnson & Johnson has a 52 week low of $144.95 and a 52 week high of $175.97. The firm has a market cap of $380.01 billion, a P/E ratio of 11.43, a P/E/G ratio of 2.63 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJGet Free Report) last posted its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, beating analysts’ consensus estimates of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The company had revenue of $21.40 billion for the quarter, compared to analyst estimates of $21.02 billion. During the same period in the prior year, the firm posted $2.35 EPS. The company’s quarterly revenue was down 9.7% on a year-over-year basis. Equities analysts expect that Johnson & Johnson will post 10.65 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th will be given a dividend of $1.19 per share. The ex-dividend date is Friday, February 16th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.02%. Johnson & Johnson’s payout ratio is presently 34.47%.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the transaction, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.20% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Royal Bank of Canada restated an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday, January 24th. Morgan Stanley dropped their price objective on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 24th. TheStreet cut shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, November 17th. Wells Fargo & Company cut shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $170.00 to $163.00 in a research note on Wednesday, December 13th. Finally, UBS Group upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $167.00 to $180.00 in a research note on Friday, December 1st. Eight research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $176.14.

View Our Latest Stock Report on JNJ

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

See Also

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.